Specificity of the autologous neutralizing antibody response

Current Opinion in HIV and AIDS

Volumn 4, Issue 5, 2009, Pages 358-363

  Moore, Penny L ^a,b   Gray, Elin S ^a,b   Morris, Lynn ^a,b  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Autologous neutralization; C3; Escape; Strain specific; Variable loops

Indexed keywords

AUTOANTIBODY; EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN V1V2;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; CROSS REACTION; DISEASE CONTROL; ESCAPE BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; SUPERINFECTION; VIREMIA; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 69549126129     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832ea7e8     Document Type: Review

References (79)

1. Gray ES, Moore PL, Choge IA, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007; 81:6187-6196. (Pubitemid 46878025)
2. Li B, Decker JM, Johnson RW, et al. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C humanimmunodeficiency virus type 1. J Virol 2006; 80:5211-5218. (Pubitemid 43752766)
3. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149. (Pubitemid 36418171)
4. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV- 1. Nature 2003; 422:307-312.
5. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma antigp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-12463. The first detailed analysis of the ontogeny of B-cell responses to transmitted HIV-1 subtype B viruses showing a relatively well defined hierarchy of binding antibody responses starting from 8 days after the detection of viremia, which precede the development of neutralizing antibody responses.
6. Frost SD, Wrin T, Smith DM, et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A 2005; 102:18514-18519. (Pubitemid 43011257)
7. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008; 82:7932-7941. An analysis of the neutralizing antibody response in relation to the evolution of the envelope, spanning the entire course of infection in five individuals, including progression to AIDS. Selection of the envelope was shown to wane late in infection. Reversion of neutralization escape mutations suggests such changes may indeed impact on viral fitness.
8. Deeks SG, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006; 80:6155-6164. (Pubitemid 43849193)
9. Davis KL, Bibollet-Ruche F, Li H, et al. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 2009; 83:1240-1259.
10. Davis KL, Gray ES, Moore PL, et al. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 2009; 387:414-426. An analysis of anti-V3 antibodies shows that these antibodies, despite having potent neutralizing capacity against viruses with exposed V3 loops, do not contribute to autologous or heterologous neutralization.
11. Moore PL, Gray ES, Choge IA, et al. The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008; 82:1860-1869. This study suggests the existence of common neutralization targets within the C3-V4 region in early subtype C infection, with potential implications for the design of vaccines targeting common exposed and immunogenic regions.
12. Laird ME, Igarashi T, Martin MA, Desrosiers RC. Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 2008; 82:11054-11065. An assessment of the specificities of the strain-specific AnAbs elicited by SHIV infection of monkeys using reciprocal chimeras suggests that this response is dominated by anti-V1V2 antibodies. The authors discuss the consequences of the involvement of a common region for potential multivalent but V1V2-specific vaccines.
13. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252. (Pubitemid 39507829)
14. Li M, Gao F, Mascola J, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10200-10209. (Pubitemid 41098552)
15. Pinter A, Honnen WJ, He Y, et al. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004; 78:5205-5215. (Pubitemid 38581472)
16. Krachmarov CP, Honnen WJ, Kayman SC, et al. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 2006; 80:7127-7135.
17. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 2005; 21:171-189.
18. Krachmarov C, Pinter A, Honnen WJ, et al. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J Virol 2005; 79:780-790. (Pubitemid 40053861)
19. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659. (Pubitemid 28289647)
20. Wyatt R, Moore J, Accola M, et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995; 69:5723-5733.
21. Sagar M, Wu X, Lee S, Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 2006; 80:9586-9598. (Pubitemid 44435633)
22. Chackerian B, Rudensey LM, Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J Virol 1997; 71:7719-7727. (Pubitemid 27391717)
23. Fung MS, Sun CR, Gordon WL, et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 1992; 66:848-856.
24. Gorny MK, Moore JP, Conley AJ, et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994; 68:8312-8320. (Pubitemid 24362725)
25. Kayman SC, Wu Z, Revesz K, et al. Presentation of native epitopes in the V1/ V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol 1994; 68:400-410. (Pubitemid 24974644)
26. Li Y, Svehla K, Mathy NL, et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006; 80:1414-1426. (Pubitemid 43134099)
27. McKeating JA, Shotton C, Cordell J, et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993; 67:4932-4944. (Pubitemid 23215975)
28. Pinter A, Honnen WJ, D'Agostino P, et al. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates. J Virol 2005; 79:6909-6917. (Pubitemid 40677322)
29. Rong R, Bibollet-Ruche F, Mulenga J, et al. Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection. J Virol 2007; 81:1350-1359. (Pubitemid 46167856)
30. Wu L, Yang ZY, Xu L, et al. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. Vaccine 2006; 24:4995-5002. (Pubitemid 43796222)
31. Bar K, Keele BF, Decker JM, et al. Neutralizing antibody recognition of V1 in early HIV-1 infection. 2009; 16th Conference on Retroviruses and Opportunistic Infections. Palais des Congres do Montreal: Montreal, Canada.
32. Gorny MK, Stamatatos L, Volsky B, et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005; 79:5232-5237. (Pubitemid 40464273)
33. Rong R, Gnanakaran S, Decker JM, et al. Unique mutational patterns in the envelope a2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol 2007; 81:5658-5668. (Pubitemid 46847005)
34. Sato S, Yuste E, Lauer WA, et al. Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J Virol 2008; 82:9739-9752.
35. Zhou T, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445:732-737. (Pubitemid 46279718)
36. Gnanakaran S, Lang D, Daniels M, et al. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol 2007; 81:4886-4891. (Pubitemid 46668687)
37. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360. (Pubitemid 34734202)
38. Kulkarni SS, Lapedes A, Tang H, et al. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology 2009; 385:505-520.
39. Huang CC, Stricher F, Martin L, et al. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 2005; 13:755-768. (Pubitemid 40704664)
40. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
41. Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 2008; 82:949-956.
42. Kwong PD. Structure-based envelope immunogens; Keystone HIV immunobiology: from infection to immune control. 2009; Keystone Resort: Keystone, Colorado, USA.
43. Gray ES, Moore PL, Madiga M, et al. Broadly cross reactive anti-MPER plasma antibodies define novel epitopes; Keystone HIV Immunobiology: from infection to immune control. 2009; Keystone Resort, Keystone, Colorado, USA.
44. Gray ES, Moore PL, Bibollet-Ruche F, et al. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an antimembrane- proximal external region-neutralizing antibody response. J Virol 2008; 82:2367-2375. (Pubitemid 351293537)
45. Delwart EL, Pan H, Sheppard HW, et al. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997; 71:7498-7508. (Pubitemid 27391690)
46. Albert J, Abrahamsson B, Nagy K, et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990; 4:107-112. (Pubitemid 20108767)
47. Arendrup M, Nielsen C, Hansen JE, et al. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992; 5:303-307.
48. Bradney AP, Scheer S, Crawford JM, et al. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis 1999; 179:1264-1267. (Pubitemid 29196512)
49. Montefiori DC, Altfeld M, Lee PK, et al. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 2003; 170:3906-3914. (Pubitemid 36359262)
50. Tremblay M, Wainberg MA. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 1990; 162:735-737. (Pubitemid 20266169)
51. Geffin R, Hutto C, Andrew C, Scott GB. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1. Virology 2003; 310:207-215. (Pubitemid 37487622)
52. Burns DP, Collignon C, Desrosiers RC. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 1993; 67:4104-4113. (Pubitemid 23180736)
53. Burns DP, Desrosiers RC. Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol 1991; 65:1843-1854.
54. Kinsey NE, Anderson MG, Unangst TJ, et al. Antigenic variation of SIV: mutations in V4 alter the neutralization profile. Virology 1996; 221:14-21.
55. Wu X, Parast AB, Richardson BA, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 2006; 80:835-844. (Pubitemid 43062895)
56. Mahalanabis M, Jayaraman P, Miura T, et al. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol 2009; 83:662-672. This study of long-term nonprogressors shows continuous antibody selection and escape occurs, and the authors propose that AnAbs may contribute to viral control in these cases.
57. Blish CA, Dogan OC, Derby NR, et al. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 2008; 82:12094-12103. A direct examination of the sensitivity of superinfecting strains to preexisting neutralizing antibody responses. Superinfection was mediated in four of five cases by viruses that showed low but detectable sensitivity to preexisting host AnAb responses, suggesting that very low cross-neutralizing titres may not be sufficient for protection against superinfection.
58. Trkola A, Kuster H, Rusert P, et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008; 82:1591-1599. The above study provides estimates, based on in-vivo passive immunization trials of monoclonal neutralizing antibodies, of the titers of neutralizing antibodies, which might be required for protection, with results very much in line with data obtained using animal studies.
59. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018. (Pubitemid 29189846)
60. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
61. Poignard P, Sabbe R, Picchio GR, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-438. (Pubitemid 29205479)
62. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766. Use of a novel measure of antiviral efficacy, applied here (in this article) to antiretroviral drugs, but with potential utility in assessing the potency of neutralizing antibodies as well. (Pubitemid 351951518)
63. Shen L, Sampah M, Siliciano RF. Quantitative analysis of the control of HIV-1 replication by neutralizing antibodies directed at the envelope protein; Keystone HIV immunobiology: from infection to immune control. 2009; Keystone Resort, Keystone, Colorado, USA.
64. Mascola JR, D'Souza P, Gilbert P, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79:10103-10107. (Pubitemid 41098551)
65. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006; 80:11776-11790. (Pubitemid 44788890)
66. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557.
67. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-3970.
68. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201:1407-1419. (Pubitemid 40664085)
69. Binley JM, Lybarger EA, Crooks ET, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651-11668.
70. Dhillon AK, Donners H, Pantophlet R, et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from HIV-1 infected donors. J Virol 2007; 81:6548-6562.
71. Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034. (Pubitemid 47517505)
72. Li Y, Svehla K, Louder MK, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045-1059.
73. Sather DN, Armann J, Ching LK, et al. Factors associated with the development of cross-reactive neutralizing antibodies during HIV-1 infection. J Virol 2008; 83:757-769.
74. Tang H, Robinson J, Gnanakaran S, et al. Single amino acid changes on the silent face of gp120 associated with autologous neutralization-escape in HIV- 1 infection; 2007; AIDS Vaccine 07; Seattle, USA.
75. Guan Y, Sajadi MM, Kamin-Lewis R, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 2009; 106:3952-3957.
76. Scheid J, Mouquet H, Feldhahn N, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009; 343:65-67.
77. Scheid JF, Mouquet H, Feldhahn N, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640.
78. Tiller T, Meffre E, Yurasov S, et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329:112-124. (Pubitemid 350235462)
79. Rademeyer C, Moore PL, Taylor N, et al. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 2007; 368:172-181. (Pubitemid 47599564)